Jones R N, Biedenbach D J, Croco M A, Barrett M S
Department of Pathology, University of Iowa College of Medicine, Iowa City, USA.
Diagn Microbiol Infect Dis. 1998 Aug;31(4):573-8. doi: 10.1016/s0732-8893(98)00044-3.
Cefditoren (formerly ME-1206), a new orally administered cephalosporin, was evaluated in vitro against 1249 recently isolated strains of Streptococcus pneumoniae (500 strains), Moraxella catarrhalis (250 strains), and Haemophilus influenzae (499 strains). Reference National Committee for Clinical Laboratory Standards methods were used and the strains were representative for the current rates of beta-lactamase production or penicillin resistance. Cefditoren had MIC50/MIC90 results for Moraxella catarrhalis and Haemophilus influenzae of 0.12/0.5 and < or = 0.008/0.015 microgram/mL, respectively. The pneumococci were consistently twofold to eightfold more susceptible to cefditoren than other oral cephalosporins or penicillins. The MIC90 for penicillin-resistant S. pneumoniae was only 2 micrograms cefditoren/mL, and the highest recorded MIC was 4 micrograms/mL. Cefditoren appears to be a very promising beta-lactam possessing the greatest potency and potential spectrum versus contemporary (1997) respiratory tract pathogens.
头孢妥仑（曾用名ME - 1206）是一种新型口服头孢菌素，我们对其进行了体外评估，测试对象为1249株近期分离出的肺炎链球菌（500株）、卡他莫拉菌（250株）和流感嗜血杆菌（499株）。采用了美国国家临床实验室标准委员会的参考方法，这些菌株代表了当前β-内酰胺酶产生率或青霉素耐药率。头孢妥仑对卡他莫拉菌和流感嗜血杆菌的MIC50/MIC90结果分别为0.12/0.5和≤0.008/0.015微克/毫升。肺炎链球菌对头孢妥仑的敏感性始终比其他口服头孢菌素或青霉素高两到八倍。对青霉素耐药的肺炎链球菌的MIC90仅为2微克头孢妥仑/毫升，记录到的最高MIC为4微克/毫升。头孢妥仑似乎是一种非常有前景的β-内酰胺类药物，对当代（1997年）呼吸道病原体具有最强的效力和潜在谱。
